TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05586451

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Traditional High Load Resistance Exercise (HLRE)
Description: Participants will then perform 75% of tested 1RM for 3 sets of 12 repetitions at a pace of 1 repetition every 2 seconds on the dominant leg with one-minute rest between sets. After completing the HLRE protocol, participants will perform 2 post-exercise maximal voluntary contractions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Traditional High Load Resistance Exercise (HLRE)
Description: Participants will then perform 75% of tested 1RM for 3 sets of 12 repetitions at a pace of 1 repetition every 2 seconds on the dominant leg with one-minute rest between sets. After completing the HLRE protocol, participants will perform 2 post-exercise maximal voluntary contractions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low Load Resistance Exercise with Blood Flow Restriction (LLBFR)
Description: Participants will then perform 25% of tested 1RM for sets of 30, 15, 15, and 15 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low Load Resistance Exercise with Blood Flow Restriction (LLBFR)
Description: Participants will then perform 25% of tested 1RM for sets of 30, 15, 15, and 15 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate Load Resistance Exercise with Blood Flow Restriction (MLBFR)
Description: Participants will then perform 50% of tested 1RM for sets of 15, 8, 7, and 7 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate Load Resistance Exercise with Blood Flow Restriction (MLBFR)
Description: Participants will then perform 50% of tested 1RM for sets of 15, 8, 7, and 7 repetitions on the dominant leg at a pace of 1 repetition every 2 seconds with one-minute rest between sets. Participants will be fitted with an occlusion cuff on the proximal portion of the thigh. The limb occlusion pressure will be set at 60% blood flow occlusion and remain occluded throughout the exercise (Delfi Medical Innovations Personal Tourniquet System).
Study: NCT05944237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0039732 Capsules
Description: HTL0039732 Capsules will be administered orally to fasted participants, although an exploration of food effects may be performed as a single dose at Cycle 0. A single dose will be administered between 3 and 9 days prior to commencement of Cycle 1. From Cycle 1 Day 1, HTL0039732 will be administered on a once daily (QD) schedule. Each administration cycle will consist of 21 days with no break between cycles. Participants may initially receive up to 18 cycles but may continue for a further 18 cycles if they are deemed to be benefitting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0039732 Capsules and atezolizumab infusion
Description: HTL0039732 Capsules will be administered orally on a QD schedule to fasted participants starting on Cycle 1 Day 1. Each administration cycle will consist of 21 days with no break between cycles. Cycle 1 will consist of HTL0039732 monotherapy. From Cycle 2 onwards, participants will also receive 1200 mg atezolizumab as an IV infusion on Day1 of each cycle (i.e. every 3 weeks). Participants may initially receive up to 18 cycles of HTL0039732 but may continue for a further 18 cycles if they are deemed to be benefitting, and they may receive up to 36 cycles of atezolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0039732 Capsules and atezolizumab infusion
Description: HTL0039732 Capsules will be administered orally on a QD schedule to fasted participants starting on Cycle 1 Day 1. Each administration cycle will consist of 21 days with no break between cycles. Cycle 1 will consist of HTL0039732 monotherapy. From Cycle 2 onwards, participants will also receive 1200 mg atezolizumab as an IV infusion on Day1 of each cycle (i.e. every 3 weeks). Participants may initially receive up to 18 cycles of HTL0039732 but may continue for a further 18 cycles if they are deemed to be benefitting, and they may receive up to 36 cycles of atezolizumab.
Study: NCT05873101

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mobilization With Movement (MWM)
Description: Mobilization With Movement

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Kelternborn Treatment Technique
Description: Kelternborn Treatment Technique
Study: NCT06316791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: single dose of CNCT19
Description: Autologous 2nd generation CD19-directed CAR-T cells, infusion intravenously.
Study: NCT04953949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NU-MAX®
Description: Topical Hemostat
Study: NCT05070273

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve conduction study
Description: NCS of nervus hypoglossus (evaluation of M-response parameters) was carried out using a 4-channel electromyographic machine. The stimulation will be carried out from three points:~1. angle of the lower jaw (proximal point),~2. the area of the carotid triangle (distal point),~3. directly from the electrode of St. Mark when it is localized on the muscles of the tongue.~The initial stimulation parameters: strength of an electric current 20 mA, stimulus duration 0.2 ms, and frequency 1 Hz. To achieve supramaximal stimulation, the stimulation strength will be increased with a step of 1-2 mA to a maximum of 35 mA, the duration of the stimulus will be increased to 0.3 ms.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation of hypoglossal nerve
Description: TMS will be carried out using a Magstim 200 magnetic stimulator connected with a BiStim module (Magstim Co. Ltd., Whitland, Wales, UK). The generated magnetic pulses will be delivered by the coil 65 mm in diameter tangentially located relative to the scalp in the F7 projection - T3 and F8-T4 (according to the international scheme 10-20). The area of cortical stimulation will be localized by supplying single pulses with gradual increase, with a coil displacement with a step of 1 cm, until the contraction of the facial muscles will be obtained, followed by the determination of the MEP threshold value. Analysis of conduction by cortical-lingual pathway will be performed at TMS with magnetic stimulus intensity 20-30% above the MEP threshold.
Study: NCT06103695

Intervention type: DRUG
Group type: OTHER
Intervention: Tapinarof
Description: Add on Vtama (tapinarof) to biololgic therapy
Study: NCT05418062

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and commitment therapy (ACT)
Description: 8 weekly 2 hour sessions of ACT group for CD patients with chronic pain. Manual available on request

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Description: 8 weekly 2 hour sessions of ACT group for CD patients with chronic pain. Manual available on request
Study: NCT04820452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose IBI302
Description: Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose IBI302
Description: High dose IBI302 intravitreal injection given as every other month after three loading monthly injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intraocular injection
Study: NCT06346028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsway H4 deep rTMS coil and Brainsway stimulator system
Description: An rTMS treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks.~Sixty trains of 30 pulses each (total 1,800 pulses) will be applied at 10 Hz, for 3 second trains, with a 15 second inter-train interval, for approximately 18 minutes of treatment time.~At each rTMS treatment session, prior to stimulation, participants will undergo a smoking craving provocation procedure where they will be asked to close their eyes and imagine one of their triggers for 30 seconds. Following this they will watch a PowerPoint presentation of smoking pictures for 2 minutes and 30 seconds. Thus, the entire craving provocation procedure will be 3 minutes prior to stimulation start.~Brief behavioural support will be available to the participant on a weekly basis by a trained research staff member from the NDC.
Study: NCT05640752

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2019 ESC guideline-determined diagnostic strategy
Description: ESC-PTP is calculated using age, sex and type of chest pain according to 2019 ESC guideline for the diagnosis and management of CCS and RF-CL is calculated using age, sex, type of chest pain, hypertension, dyslipidemia, diabetes, smoking and family history of CAD based on the publication of Winther et al., respectively. According to ESC strategy, subjects with ESC-PTP ≤5% are classified into low risk group and ones with ESC-PTP ≥15% are classified into high risk group. For subjects with ESC-PTP of 5%-15%, ones with RF-CL ≥15% are classified into high risk group and ones with RF-CL \<15% are classified into low risk group. CCTA should be referred for a subject in high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2016 NICE guideline-determined diagnostic strategy
Description: For subjects assigned to NICE strategy, ones with nonanginal chest pain and normal ECG were classified into low risk group and ones with typical and atypical angina or nonanginal chest pain with abnormal ECG were classified into high risk group. Subjects determined to be at low risk will be referred to optimal medication treatment with no immediate CCTA.
Study: NCT04898829

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU explore
Description: For 28 consecutive days, participants will take their usual restricted therapeutic diet, either:~- Replacing their usual second stage concentrated protein substitute with PKU explore~OR~- Commencing PKU explore and gradually reducing their Phe-free formula for infants.
Study: NCT04797884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraBionic Device
Description: Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at one of the recruiting site, all other treatments will be self-administered at the patient's home.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Device
Description: Each treatment day consists of three courses of 60-minute treatments to be administered in the morning, at noon, and in the evening. Each 6-week treatment period will be considered a cycle of treatment. With the exception of the first 60-minute treatment, which will be delivered at the recruiting site, all other treatments will be self-administered at the patient's home.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Quality of Life Assessment
Description: Ancillary services

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary services
Study: NCT06236412

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Health education about the contents listed under each arm will be provided for the participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Health education about the contents listed under each arm will be provided for the participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Health education about the contents listed under each arm will be provided for the participants.
Study: NCT06532968

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham
Study: NCT06270771

Intervention type: DEVICE
Intervention: OURA Ring
Description: The OURA ring (https://ouraring.com) is a light-weight wearable device in the form of a ring that has several microsensors enabling detection of heart rate, blood oxygen level, skin temperature, and movement. The OURA ring and application can synthesize the sensory data to generate physiologic information such as sleep, activity level, resting heart rate, heart rate variability, respiratory rate, and more. The OURA ring is water resistant and has up to 5-7 days of battery life and can be fully charged in 20-80 minutes. It communicates with the OURA app and commonly used Smartphone health apps via Bluetooth connectivity with automatic syncing every week.
Study: NCT06532968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORION spinal lamina cover
Description: an artificial lamina coverage of the ORION spinal system
Study: NCT06193187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril and Valsartan Sodium Tablets 24 mg/26 mg
Description: Test (T)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril and Valsartan Sodium Tablets 24 mg/26 mg
Description: Test (T)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entresto 50 mg
Description: Reference (R)
Study: NCT06193187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entresto 50 mg
Description: Reference (R)
Study: NCT05530941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online suicide prevention campaign
Description: The online prevention campaign consists of two campaign videos, a website with information about suicide prevention and mental health tailored to men, and testimonials of men who struggled with their mental health.
Study: NCT06286761

Intervention type: OTHER
Intervention: endothelial cell collection
Description: Participants may opt to have testing performed including blood sampling, intravenous catheter placement with endothelial cell collection, oral glucose tolerance test, consuming a test meal, having imaging performed such as MRI, DEXA, MRS to investigate use of different assays, different sample treatment approaches to determine optimal conditions that produce the most accurate and reproducible results, and/or repeat testing on different days or with different equipment that measures the same variable.
Study: NCT05548296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACR-368
Description: ACR-368 is an experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACR-368
Description: ACR-368 is an experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OncoSignature
Description: Biomarker profile based on prediction of drug sensitivity performed on biopsy tissue

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OncoSignature
Description: Biomarker profile based on prediction of drug sensitivity performed on biopsy tissue
Study: NCT04981912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDMP + rituximab as a means of debulking prior to initiating venetoclax.
Description: * Patients will receive HDMP + Rituximab for 1 cycle, followed by reassessment of Tumor Burden,~* If Tumor Burden classification is low after HDMP + Rituximab (lymph nodes \< 5cm in diameter AND absolute lymphocyte count \< 25k/uL), patients will initiate venetoclax dose ramp-up, with ramp-up schedule according to venetoclax package insert.~* Patients who still have a disease burden (lymphadenopathy \> 5 cm or ALC \> 25k/iL) that meets criteria for medium or high risk of TLS after 1 cycle of HDMP + Rituximab are given the option to repeat a 2nd cycle of HDMP + Rituximab prior to venetoclax dose ramp-up.
Study: NCT05368935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: 500 mg Twice Daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: 500 mg Twice Daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: 500 mg Twice Daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: 500 mg Twice Daily for 7 days
Study: NCT06373679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Switching to E-Cigarette
Description: Participants will receive eleven weeks of e-cigarette products with instructions to switch completely at switch date

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Switching using Medication
Description: Participants will receive eleven weeks of FDA approved medication, either varenicline or combination NRT, with instructions to quit smoking cigarettes at quit date
Study: NCT05189080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message reminders
Description: Text messages will be sent to parents/guardians of children ages 0 to 17 years who no-showed for their well child visits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interviews
Description: Interviews will be conducted with a subset of participants to identify the top one or two performing text messages.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Alongside notification text messages regarding no-showed visits, participants will be invited to participate in a survey about their experience with the health system. This survey will assess reasons for missing the WCV and primary caregiver's perspective on the experience at the prior visit.
Study: NCT05819281

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic blend
Description: (Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium lactis, Bifidobacterium bifidum e Lactobacillus rhamnosus - Final concentration: 1 x 1010 CFU/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Maltodextrin
Study: NCT05590494

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasonic tenotomy
Description: Ultrasonic procedure as part of standard of care, as clinically indicated, to stimulate healing of the partial tear. The procedure uses ultrasound guidance that allows a needlelike device to gradually break up and remove tendinopathic tendon tissue.
Study: NCT06324747

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular socket therapy
Description: Vestibular socket therapy will be used for the intervention.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional full thickness flap
Description: reflecting the mucoperiosteum to access the extraction socket
Study: NCT05332886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MetaHealth Group
Description: Three metaverse rooms will be created via metaverse technology that aims to develop healthy nutrition, physical activity, and psychological resilience skills to reduce the risk of of NCDs in youth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MobileHealth Group
Description: The intervention aims to develop healthy nutrition, physical activity, and psychological resilience skills using mobile application materials to reduce the risk of NCDs in youth.
Study: NCT06324331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decidual sparing
Description: Endometrial free uterine closure technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non decidual sparing
Description: Routine uterine closure technique including endometrium
Study: NCT04823182

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Magnetic Resonance Imaging
Description: The Cardiac MRI protocol consists of static T2 weighted in all three planes and T2 weighted imaging with fat saturation in the short axis plane.
Study: NCT05820607

Intervention type: BIOLOGICAL
Intervention: Microbiome, metabolome, transcriptome, genome
Description: Fecal genome, serum metabolome, leukocyte transcriptome, gastric mucosa genome

Intervention type: BIOLOGICAL
Intervention: Microbiome, metabolome, transcriptome, genome
Description: Fecal genome, serum metabolome, leukocyte transcriptome, gastric mucosa genome

Intervention type: BIOLOGICAL
Intervention: Microbiome, metabolome, transcriptome, genome
Description: Fecal genome, serum metabolome, leukocyte transcriptome, gastric mucosa genome
Study: NCT06390033

Intervention type: DEVICE
Intervention: Prosthetic foot
Description: A low-cost prosthetic foot designed to enhance gait mechanics and physical performance in individuals who have undergone traumatic unilateral transtibial amputation, as compared to the traditional K2 - K3 prosthetic feet currently available on the market, during both indoor and outdoor activities, whilst satisfying the users' satisfaction levels after traumatic unilateral transtibial amputation.

Intervention type: DEVICE
Intervention: Prosthetic foot
Description: A low-cost prosthetic foot designed to enhance gait mechanics and physical performance in individuals who have undergone traumatic unilateral transtibial amputation, as compared to the traditional K2 - K3 prosthetic feet currently available on the market, during both indoor and outdoor activities, whilst satisfying the users' satisfaction levels after traumatic unilateral transtibial amputation.
Study: NCT05446441

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic surgery;
Description: Endoscopic thyroidectomy group is the papillary thyroid carcinoma patient group who underwent endoscopic thyroid surgery using a gasless, trans-axillary approach.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery;
Description: Endoscopic thyroidectomy group is the papillary thyroid carcinoma patient group who underwent endoscopic thyroid surgery using a gasless, trans-axillary approach.